Patents by Inventor Kenneth A. Smiles

Kenneth A. Smiles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for the treatment of infection caused by Hepatitis B virus (HBV)
    Patent number: 5432165
    Abstract: The present invention relates to pharmaceutical compositions useful for the treatment of subjects suffering from an infection or disease caused by the hepatitis B virus (HBV). In particular, it has been discovered that the administration of low dosage amounts of 1-(2'-deoxy-2'-fluoro-.beta.-D-arabinofuranosyl)-5-iodouracil (FIAU) to humans chronically infected with HBV is effective to reduce drastically circulating markers associated with HBV. The present invention is also directed to methods of the preparation of pharmaceutical antiviral compositions.
    Type: Grant
    Filed: October 9, 1992
    Date of Patent: July 11, 1995
    Assignee: Oclassen Pharmaceuticals, Inc.
    Inventors: Dennis W. Adair, Kenneth A. Smiles, Dannie H. King
  • Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
    Patent number: 5256410
    Abstract: Human squamous cell carcinoma is successfully treated by intralesional administration of recombinant human interferon alpha-2b.
    Type: Grant
    Filed: May 20, 1991
    Date of Patent: October 26, 1993
    Assignee: Schering Corporation
    Inventors: Daniel J. Tanner, Edwin A. Peets, Kenneth A. Smiles
  • Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
    Patent number: 5028422
    Abstract: This invention relates to a method of treating basal cell carcinoma with purified human recombinant DNA interferon alpha-2, preferably purified human recombinant DNA interferon alpha-2b by administering intralesionally (by injection) to a patient in need of such treatment, a sufficient amount of the purified human recombinant DNA alpha interferon, preferably recombinant DNA interferon alpha-2b, to be effective as an antitumor agent.
    Type: Grant
    Filed: April 13, 1989
    Date of Patent: July 2, 1991
    Assignee: Schering Corporation
    Inventors: Daniel J. Tanner, Edwin A. Peets, Kenneth A. Smiles
  • Treatment of actinic keratoses with alpha.sub.2 interferon
    Patent number: 5002764
    Abstract: A method of treating actinic keratoses with alpha.sub.2 interferon is disclosed.
    Type: Grant
    Filed: August 22, 1989
    Date of Patent: March 26, 1991
    Assignee: Schering Corporation
    Inventors: Edwin A. Peets, Kenneth A. Smiles, Daniel J. Tanner
  • Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
    Patent number: 4959210
    Abstract: Condylomata Acuminata infections (anogenital warts) are treated in infected patients by administering liquid nitrogen and immediately thereafter beginning administering recombinant DNA human alpha interferon thrice a week for three weeks.The interferon exemplified is recombinant DNA human interferon alfa-2b in which 1.0.times.10.sup.6 International Units are administered by injection to each lesion.The liquid nitrogen is the cryosurgical agent exemplified and it is topically administered to each lesion by conventional means.
    Type: Grant
    Filed: November 1, 1988
    Date of Patent: September 25, 1990
    Assignee: Schering Corporation
    Inventors: Kenneth A. Smiles, Edwin A. Peets, Daniel J. Tanner